The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19 disease.COVID-19, virus not identifiedU07.2
- Registration Number
- IRCT20200506047323N3
- Lead Sponsor
- Bandare-abbas University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Age =18 years
Positive polymerase chain reaction (PCR) test for COVID-19
Primary clinical symptoms
Hospitalized
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm
Exclusion Criteria
Underlying diseases, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers
Acute and chronic renal failure
Peptic ulcers
History of allergy to studied drugs
Pregnancy and breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral load. Timepoint: Before intervention and day 7 after the intervention?. Method of measurement: Polymerase chain reaction (PCR) test.;Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: Time period from admission to discharge. Method of measurement: Patient's file.;C-reactive protein. Timepoint: Before intervention and day 7 after the intervention. Method of measurement: C-RP kit.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.